Epigenetics Market size was valued at USD 2.36 billion in 2024 and is likely to cross USD 13.72 billion by 2037, expanding at more than 14.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of epigenetics is estimated at USD 2.63 billion.
With cancer becoming more common and the need for better treatments growing, scientists are looking closer at epigenetics. Epigenetic drugs hold promise for figuring out who's at risk for cancer, finding it early, and tracking how well treatment is working. This innovative approach is not confined to oncology alone; researchers are broadening the scope to include potential therapies for diseases like diabetes, infections, and cardiovascular conditions. This expanding field presents a promising avenue for investment and development in the pharmaceutical sector, highlighting a shift towards more precise and personalized medicine strategies.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.5% |
|
Base Year Market Size (2024) |
USD 2.36 billion |
|
Forecast Year Market Size (2037) |
USD 13.72 billion |
|
Regional Scope |
|
Therapy Type (HDAC, DNMT)
HDAC segment is likely to hold more than 67% epigenetics market share by 2037. It is expected to around USD 3 billion by 2037, growing at a CAGR of 8%. The growth in this sector is due to HDAC inhibitors showing great results in fighting various cancers, including blood cancers and tumors. The US FDA has given the green light to HDAC inhibitors for treating different cancers, like cutaneous T cell lymphoma (CTCL). Moreover, new methods have made HDAC inhibitors more efficient in tackling specific diseases, enhancing their performance.
Applications (Oncology, Non-Oncology)
By the end of 2037, oncology segment is projected to capture around 70% epigenetics market share. The segment growth is fueled by a rising need for drugs based on gene control in both spotting and treating cancer. This market expansion is shaped by the push towards more precise medicine and therapies aimed directly at cancer traits. This shift towards precision medicine and focused treatments spurs the necessity for gene control analysis, thus boosting the growth of the oncology application section. Meanwhile, the non-oncology application sub-segment is also on an upward trend. It expected to grow at a rate of 15.30% from 2024 to 2030. This growth reflects a broad interest in refining treatment strategies across various medical fields, emphasizing the crucial role of gene control studies in modern healthcare advancements.
Diagnostic Technologies (DNA Methylation, CHIP, Others)
In epigenetics market, DNA methylation segment is estimated to capture over 46.8% revenue share by 2037. The segment growth is linked to the growing use of DNA methylation in drug research and production, along with the drop in genome sequencing costs, boosts market expansion. In 2024, the DNA Methylation Sequencing market stood at USD 1.21 billion and is projected to hit USD 3.6 billion by 2032, marking a CAGR of 17.3% from 2024 to 2032. Currently, the market offers several in vitro diagnostic tests that utilize DNA methylation analysis of specific genes. DNA methylation plays a crucial role in gene control as a fundamental epigenetic change. Progress in DNA methylation detection methods is making diagnostic tests more precise and sensitive, thereby improving their ability to pinpoint epigenetic changes tied to illnesses.
Our in-depth analysis of the market includes the following segments:
|
Therapy Type |
|
|
Applications |
|
|
Diagnostic Technologies |
|
|
End Users |
|
North America Market Statistics
North America industry is estimated to dominate majority revenue share of 47% by 2037. The leading position of this region comes from its top-notch health care systems, key firms engaging in epigenetics research and development, and the growing use of cutting-edge molecular tech by pharmaceutical and biotech sectors. Research efforts on how microorganisms fight drugs, cancer biology, and finding new medicines outside of cancer care fuel the market's expansion in North America. The area's high-standard health care framework bolsters the growth and use of epigenetic methods and treatments. With cancer rates rising in North America, there's a pressing need for improved diagnostic methods and treatments, making epigenetics a vital part of cancer studies.
The United States leads the market in North America thanks to major industry players and heightened research activities. In 2023, the market in the U.S. was worth USD 500 million and is anticipated to grow to USD 2,050 million by 2033, reflecting the country's strong focus on cancer genomics research expected to boost epigenetics' role in studies and market size.
The Canadian market was worth about USD 800 million in 2022 and is forecasted to hit USD 2000.5 million by 2030, growing at a rate of 12% during the period. This showcases Canada's commitment to advancing in this field alongside its North American counterpart, highlighting the region's overall strength in health innovation and epigenetics research.
European Market Analysis
The European region will also encounter huge growth for the epigenetics market during the forecast period and will hold the second position due to an increase in long-lasting diseases needing exact diagnosis. It is expected to grow at a pace of 13% yearly, aiming for a value of USD 353 million in 2028 from USD 190 million in 2023. The rise in knowledge about epigenetics and its role in identifying and treating diseases boosts its market growth in Europe. Additionally, the growth is fueled by the European government's backing for biotech and research efforts.
Germany stands out in the European epigenetics scene, thanks to its large pharmaceutical companies, robust research setup, and the widespread occurrence of chronic conditions. The country places a strong focus on research concerning genetic testing markers, including DNA, histones, and non-coding RNA.
The UK's epigenetics sector was worth about USD 260.9 million in 2022 and is expected to double to USD 541.5 million by 2030, growing at a steady rate of 10% from 2023 to 2030.
Several large drug companies include epigenetics studies within their wider cancer or other health issue programs. Moreover, a few smaller firms dedicate their entire focus to epigenetics. These efforts reflect the rapidly evolving nature of the field and its significant potential for transforming therapeutic approaches, underscoring the critical role of both large and small entities in advancing our understanding and treatment of diseases through epigenetic science.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?